Kynurenine pathway in major depression: Evidence of impaired neuroprotection
Authors:
- Aye-Mu MyintAMAye-Mu Myint
- Yong Ku KimYKYong Ku Kim
- Robert VerkerkRVRobert Verkerk
- Simon ScharpéSSSimon Scharpé
- Harry SteinbuschHSHarry Steinbusch
- Brian LeonardBLBrian Leonard
- 1 February 2007
- journal article
- Published by Elsevier in Journal of Affective Disorders
- Vol. 98 (1-2) , 143-151
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Th1, Th2, and Th3 cytokine alterations in major depressionJournal of Affective Disorders, 2005
- Increase in Interleukin-1β in Late-Life DepressionAmerican Journal of Psychiatry, 2005
- Early increase in vegetative symptoms predicts IFN-α-induced cognitive-depressive changesPsychological Medicine, 2004
- IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicityMolecular Psychiatry, 2004
- Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophreniaNeurobiology of Disease, 2004
- Cytokine Production and Treatment Response in Major Depressive DisorderNeuropsychopharmacology, 2000
- Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?Immunology Today, 1999
- QUINOLINIC ACID AND KYNURENINE PATHWAY METABOLISM IN INFLAMMATORY AND NON-INFLAMMATORY NEUROLOGICAL DISEASEBrain, 1992
- Dietary tryptophan level and the enzymes of tryptophan NAD pathwayBritish Journal of Nutrition, 1980
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960